12.12
price down icon5.01%   -0.625
 
loading
Gyre Therapeutics Inc stock is traded at $12.12, with a volume of 21,757. It is down -5.01% in the last 24 hours and up +21.23% over the past month. Gyre Therapeutics Inc is a biopharmaceutical company headquartered in San Diego, CA, that is primarily focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis), formerly known as Nonalcoholic Steatohepatitis (NASH)) in the United States. In the United States, Hydronidone is currently being evaluated for the treatment of liver fibrosis across a broad spectrum of chronic liver diseases under an active Investigational New Drug (IND) application. Gyre is also advancing a diverse pipeline in China through a controlling interest in the Beijing Continent, including pirfenidone, F573, F528, and F230.
See More
Previous Close:
$12.75
Open:
$12.54
24h Volume:
21,757
Relative Volume:
0.21
Market Cap:
$1.09B
Revenue:
$106.66M
Net Income/Loss:
$15.16M
P/E Ratio:
129.68
EPS:
0.0935
Net Cash Flow:
$6.37M
1W Performance:
+5.22%
1M Performance:
+21.23%
6M Performance:
+22.33%
1Y Performance:
+1.26%
1-Day Range:
Value
$12.11
$12.54
1-Week Range:
Value
$11.26
$13.07
52-Week Range:
Value
$8.26
$26.37

Gyre Therapeutics Inc Stock (GYRE) Company Profile

Name
Name
Gyre Therapeutics Inc
Name
Phone
(619) 949-3681
Name
Address
12770 HIGH BLUFF DRIVE, SUITE 150, SAN DIEGO
Name
Employee
391
Name
Twitter
Name
Next Earnings Date
2024-11-04
Name
Latest SEC Filings
Name
GYRE's Discussions on Twitter

Compare GYRE with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
GYRE
Gyre Therapeutics Inc
12.12 1.09B 106.66M 15.16M 6.37M 0.0935
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
474.30 123.91B 10.63B -479.80M -1.35B -1.99
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
715.62 78.94B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
651.00 39.98B 1.86B -40.29M -1.28B -0.85
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
274.97 35.89B 2.09B -332.26M 16.06M -2.62
Biotechnology icon
BNTX
Biontech Se Adr
118.75 28.75B 3.30B -501.07M 1.03B -2.1146

Gyre Therapeutics Inc Stock (GYRE) Upgrades & Downgrades

Date Action Analyst Rating Change
Apr-29-21 Resumed Stephens Overweight
Feb-10-21 Initiated Piper Sandler Overweight
May-21-20 Initiated Raymond James Outperform
Jan-04-19 Initiated Oppenheimer Outperform
Feb-12-18 Reiterated B. Riley FBR, Inc. Buy
Feb-09-18 Reiterated Chardan Capital Markets Buy
Dec-08-17 Initiated B. Riley FBR, Inc. Buy
Jun-12-17 Initiated Chardan Capital Markets Buy
Jun-06-17 Initiated Ladenburg Thalmann Buy
Jun-30-16 Initiated Rodman & Renshaw Buy
View All

Gyre Therapeutics Inc Stock (GYRE) Latest News

pulisher
Feb 06, 2025

Gyre therapeutics president Ma Songjiang sells $48,029 in stock By Investing.com - Investing.com South Africa

Feb 06, 2025
pulisher
Feb 06, 2025

Gyre therapeutics president Ma Songjiang sells $48,029 in stock - Investing.com

Feb 06, 2025
pulisher
Feb 05, 2025

Gyre Therapeutics, Inc. (NASDAQ:GYRE) Short Interest Up 14.4% in January - MarketBeat

Feb 05, 2025
pulisher
Feb 05, 2025

Insider Selling: Gyre Therapeutics, Inc. (NASDAQ:GYRE) President Sells 2,000 Shares of Stock - MarketBeat

Feb 05, 2025
pulisher
Feb 02, 2025

Gyre Therapeutics, Inc. (NASDAQ:GYRE) President Sells $22,360.00 in Stock - MarketBeat

Feb 02, 2025
pulisher
Jan 30, 2025

Gyre Therapeutics president sells $45,380 in stock - MSN

Jan 30, 2025
pulisher
Jan 30, 2025

Gyre Therapeutics president sells $45,380 in stock By Investing.com - Investing.com Australia

Jan 30, 2025
pulisher
Jan 29, 2025

Gyre Therapeutics president Ma Songjiang sells $42,760 in stock - MSN

Jan 29, 2025
pulisher
Jan 27, 2025

Gyre Therapeutics president Ma Songjiang sells $42,760 in stock By Investing.com - Investing.com Australia

Jan 27, 2025
pulisher
Jan 27, 2025

Gyre Therapeutics, Inc. (NASDAQ:GYRE) President Songjiang Ma Sells 2,000 Shares - MarketBeat

Jan 27, 2025
pulisher
Jan 25, 2025

Songjiang Ma Sells 2,000 Shares of Gyre Therapeutics, Inc. (NASDAQ:GYRE) Stock - MarketBeat

Jan 25, 2025
pulisher
Jan 24, 2025

Gyre Therapeutics president Ma Songjiang sells shares worth $42,960 By Investing.com - Investing.com Nigeria

Jan 24, 2025
pulisher
Jan 24, 2025

Gyre Therapeutics president Ma Songjiang sells shares worth $42,960 - MSN

Jan 24, 2025
pulisher
Jan 24, 2025

Barclays PLC Has $116,000 Stock Holdings in Gyre Therapeutics, Inc. (NASDAQ:GYRE) - Defense World

Jan 24, 2025
pulisher
Jan 22, 2025

Gyre Therapeutics president Ma Songjiang sells shares for $42,860 - MSN

Jan 22, 2025
pulisher
Jan 21, 2025

Gyre Therapeutics president Ma Songjiang sells shares for $42,860 By Investing.com - Investing.com Australia

Jan 21, 2025
pulisher
Jan 20, 2025

Gyre Therapeutics, Inc. (NASDAQ:GYRE) Short Interest Up 14.4% in December - MarketBeat

Jan 20, 2025
pulisher
Jan 20, 2025

Gyre Therapeutics president Ma Songjiang sells $42,480 in stock - MSN

Jan 20, 2025
pulisher
Jan 17, 2025

Gyre Therapeutics president Ma Songjiang sells $42,480 in stock By Investing.com - Investing.com South Africa

Jan 17, 2025
pulisher
Jan 14, 2025

Gyre Therapeutics president Songjiang Ma sells $11,156 in stock By Investing.com - Investing.com South Africa

Jan 14, 2025
pulisher
Jan 14, 2025

Songjiang Ma Sells 1,057 Shares of Gyre Therapeutics, Inc. (NASDAQ:GYRE) Stock - MarketBeat

Jan 14, 2025
pulisher
Jan 14, 2025

Gyre Therapeutics president Songjiang Ma sells $11,156 in stock - Investing.com

Jan 14, 2025
pulisher
Jan 09, 2025

Barclays PLC Has $116,000 Stock Position in Gyre Therapeutics, Inc. (NASDAQ:GYRE) - Defense World

Jan 09, 2025
pulisher
Jan 08, 2025

Gyre Therapeutics president Ma Songjiang sells $22,336 in stock - Investing.com

Jan 08, 2025
pulisher
Jan 07, 2025

Geode Capital Management LLC Has $3.81 Million Stock Position in Gyre Therapeutics, Inc. (NASDAQ:GYRE) - Defense World

Jan 07, 2025
pulisher
Jan 06, 2025

Leadership Changes at Gyre Therapeutics Amid Strategic Shift - TipRanks

Jan 06, 2025
pulisher
Jan 06, 2025

Gyre Therapeutics (NASDAQ:GYRE) Shares Down 3.2%Time to Sell? - MarketBeat

Jan 06, 2025
pulisher
Jan 06, 2025

Gyre Therapeutics Reshapes Leadership: Appoints String Capital's Ping Zhang as Lead Director - StockTitan

Jan 06, 2025
pulisher
Jan 03, 2025

Gyre Therapeutics president Ma Songjiang sells $49,600 in stock By Investing.com - Investing.com Australia

Jan 03, 2025
pulisher
Jan 03, 2025

State Street Corp Grows Position in Gyre Therapeutics, Inc. (NASDAQ:GYRE) - Defense World

Jan 03, 2025

Gyre Therapeutics Inc Stock (GYRE) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading

Gyre Therapeutics Inc Stock (GYRE) Insider Trading

Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total
Ma Songjiang
President
Feb 04 '25
Sale
11.62
2,000
23,240
2,885,138
Ma Songjiang
President
Jan 31 '25
Sale
11.51
2,000
23,020
2,889,138
Ma Songjiang
President
Feb 03 '25
Sale
11.47
2,000
22,940
2,887,138
Ma Songjiang
President
Jan 29 '25
Sale
11.43
2,000
22,860
2,893,138
Ma Songjiang
President
Jan 30 '25
Sale
11.37
2,000
22,740
2,891,138
Ma Songjiang
President
Jan 28 '25
Sale
11.51
2,000
23,020
2,895,138
Ma Songjiang
President
Jan 27 '25
Sale
11.18
2,000
22,360
2,897,138
Ma Songjiang
President
Jan 24 '25
Sale
10.89
2,000
21,780
2,899,138
Ma Songjiang
President
Jan 23 '25
Sale
10.49
2,000
20,980
2,901,138
Ma Songjiang
President
Jan 21 '25
Sale
10.85
2,000
21,700
2,905,138
$80.45
price down icon 0.35%
$20.10
price down icon 2.83%
$349.52
price down icon 1.19%
$4.7595
price down icon 5.65%
biotechnology ONC
$223.00
price down icon 2.49%
$118.71
price down icon 0.86%
Cap:     |  Volume (24h):